The short version of lyophilization fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-26 and is reviewed periodically as new material appears.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
== Skeptical view of therapeutic touch == In examinations of the existing literature on therapeutic touch, it has been observed that these studies tend only to cite research that favours the desired findings. There have been studies focused on therapeutic touch that have failed to include any research that has contradictory findings, despite their obligation to report it. Some studies, have also lacked appropriate controls, and so have appeared at first glance to show the effectiveness of therapeutic touch, yet have returned nonsignificant results when replicated; this is the case with the Grad, Cadoret, and Paul study. Researcher bias has been found in studies examining therapeutic touch. A study on therapeutic touch by Wirth, in which more than half of the subjects being treated by this therapy had healed by day 16, with no healing shown in the control group, appeared successful. However, closer examination reveals that there were several trials conducted, that only two of the five trials were successful, and that the control group healed as well or better than the treatment group in the other three trials. Similarly, Turner declared that a successful result of his work would provide "the first real scientific evidence there is for therapeutic touch," suggesting bias. Much such research has also failed to be replicated.
The B1 receptor (also called bradykinin receptor B1) is expressed only as a result of tissue injury, and is presumed to play a role in chronic pain. This receptor has been also described to play a role in inflammation. It was shown that the kinin B1 receptor recruits neutrophils via the chemokine CXCL5 production. Moreover, endothelial cells have been described as a potential source for this B1 receptor-CXCL5 pathway. The B2 receptor is constitutively expressed and participates in bradykinin's vasodilatory role. The kinin B1 and B2 receptors belong to G protein coupled receptor (GPCR) family.
=== Safety === Mild to moderate gastrointestinal side effects (such as nausea, cramping, bloating, and abdominal discomfort) are common after ESG (reported in over 70% of patients), but these are predictable, temporary, and can be managed with medications. Most will resolve within one week after ESG. Due to the minimally invasive nature of ESG, serious complications are rare. These include pain or nausea requiring hospitalization (1.08%); upper gastrointestinal tract bleeding (0.56%); peri-gastric leak or infected fluid collection (0.48%); pulmonary embolism (0.06%); perforation (0.06%). Similar rates of serious adverse events were reported in the multicenter, randomized controlled MERIT study. No deaths have been observed in the published ESG literature.
=== Indirect separation of enantiomer === Indirect enantiomer separation involves the interaction between the chiral analyte (CA) of interest and the suitable reactive CS (in this case it is an enantiopure chiral derivatizing agent, CDA) leading to the formation of a covalent diastereomeric complex that can be separated with an achiral chromatographic technique. Therapeutic agents often contain reactive functional groups (amino, hydroxyl, epoxy, carbonyl and carboxylic acid, etc.) in their structures. They are converted into covalently bonded diastereomeric derivatives using enantiomerically pure chiral derivatizing agent. The diastereomers thus formed unlike enantiomers, exhibit different physicochemical properties in an achiral environment and are eventually separated as a result of differential retention time on a stationary phase. The success of this approach depends on the availability of stable enantiopure chiral derivatizing agent (CDA) and on the presence of a suitable reactive functional group in the chiral drug molecule for covalent formation of diastereomeric derivative. The reaction of a racemic, (R,S)- Drug with a chirally and chemically pure chiral derivatizing agent, (R')-CDA, will afford diastereomeric products, (R)-Drug-(R')-CDA + (S)-Drug-(R')- CDA. The chiral derivatization reaction scheme is illustrated in the box on the right hand side. In contrast to enantiomers, diastereomers have different physicochemical properties that make them separable on regular achiral stationary phases.
Sources: en.wikipedia.org
These two components, used together, allow a much finer degree of substance identification than either unit used separately. It is not possible to make an accurate identification of a particular molecule by gas chromatography or mass spectrometry alone. The mass spectrometry process normally requires a very pure sample while gas chromatography using a traditional detector (e.g. Flame ionization detector) cannot differentiate between multiple molecules that happen to take the same amount of time to travel through the column (i.e. have the same retention time), which results in two or more molecules that co-elute. Sometimes two different molecules can also have a similar pattern of ionized fragments in a mass spectrometer (mass spectrum). Combining the two processes reduces the possibility of error, as it is extremely unlikely that two different molecules will behave in the same way in both a gas chromatograph and a mass spectrometer. Therefore, when an identifying mass spectrum appears at a characteristic retention time in a GC–MS analysis, it typically increases certainty that the analyte of interest is in the sample.
=== DNA barcoding and genomics === DNA sequences derived from fungarium specimens can link preserved material to molecular characters used in identification and phylogenetic studies, extending the scientific value of collections beyond traditional morphological characters. Sequencing named fungarium specimens can also expand public reference-sequence databases, improving the interpretation of environmental fungal DNA that would otherwise remain unidentified or only insufficiently identified. DNA in historical specimens is often degraded into short fragments of 40–400 base pairs. Genetic quality is influenced by the specimen's age as well as past exposure to heat, chemicals, or moisture. Consequently, older specimens are less likely to yield uncontaminated internal transcribed spacer (ITS) sequences than more recent collections, often producing DNA from contaminant organisms instead. DNA degradation depends not only on age but also on how specimens were collected, dried, stored, and treated against pests, because historical methods often prioritized preservation of morphology rather than nucleic-acid integrity. Conventional PCR amplification and Sanger sequencing can be difficult or impossible for some specimens, including some type material, owing to fragmentation and contamination by exogenous fungal DNA.
=== Required components === An automated insulin delivery system consists of three distinct components: a continuous glucose monitor to determine blood sugar levels, a pump to deliver insulin, and an algorithm that uses the data from the CGM and pump to determine needed insulin adjustments. In the United States, the Food and Drug Administration (FDA) allows each component to be approved independently, allowing for more rapid approvals and incremental innovation.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.